中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
21期
47-49
,共3页
张爱文%侯瑞田%巨名飞%张娜%白云
張愛文%侯瑞田%巨名飛%張娜%白雲
장애문%후서전%거명비%장나%백운
舒张性心力衰竭%重组人脑B型利钠肽%B型脑利钠肽%C反应蛋白%6min步行距离
舒張性心力衰竭%重組人腦B型利鈉肽%B型腦利鈉肽%C反應蛋白%6min步行距離
서장성심력쇠갈%중조인뇌B형리납태%B형뇌리납태%C반응단백%6min보행거리
diastolic heart failure%recombinant human B-type natriuretic peptide%B-type natriuretic peptide%C-reactive protein%6 minutes walk quantity
目的 探讨重组人脑利钠肽( rhBNP )治疗舒张性心力衰竭( DHF )的临床疗效及对B型脑利钠肽(BNP)、C反应蛋白( CRP )水平的影响.方法 选取医院收治的DHF患者190例,据就诊日期随机分为观察组98例和对照组92例,均给予常规抗心力衰竭治疗,观察组患者加用rhBNP,7 d后行超声心动图检查,并采血检测BNP和CRP水平,判定临床疗效.结果 治疗1周后,观察组超声心动图检查等容舒张时间( IVRT )为(83. 5 ± 9. 7)ms,E峰减速时间( DT )为(125. 7 ± 14. 2)ms,显著低于对照组的(90. 4 ± 10. 2)ms和(154. 6 ± 15. 5)ms (P<0.05),而舒张早期心室充盈血流峰值/舒张晚期血流峰值(E/A)为1.37±0.24,显著高于对照组的1.10±0.21(P<0.05);观察组治疗后的 BNP为(89. 2 ± 21. 1)pg/mL,CRP为(4. 8 ± 1. 6)mg/L,明显低于对照组的(107. 2 ± 24. 6)pg/mL和(7. 3 ± 2. 3)mg/L ( P < 0. 05);观察组治疗后的心率(HR)为(74. 8 ± 13. 6)次 /分,收缩压(SBP)为(109. 5 ± 18. 3)mmHg,明显低于对照组的( 80. 4 ± 12. 0 )次/分和(113. 3 ± 15. 7)mmHg( P<0. 05);6 min 步行距离为(327. 4 ± 58. 4)m,显著高于对照组的(295. 3 ± 60. 1)m ( u=3. 730,P<0. 01);两组患者低血压、转氨酶升高等不良反应率比较,差异无统计学意义(χ2 =0. 009,P=0. 923);观察组治疗总有效率为92. 86%,显著高于对照组的83. 70%(χ2=3. 890,P=0. 049).结论 rhBNP治疗DHF能有效降低神经内分泌激素和炎性水平,改善心室舒张功能,提高运动耐量,疗效显著,且安全可靠.
目的 探討重組人腦利鈉肽( rhBNP )治療舒張性心力衰竭( DHF )的臨床療效及對B型腦利鈉肽(BNP)、C反應蛋白( CRP )水平的影響.方法 選取醫院收治的DHF患者190例,據就診日期隨機分為觀察組98例和對照組92例,均給予常規抗心力衰竭治療,觀察組患者加用rhBNP,7 d後行超聲心動圖檢查,併採血檢測BNP和CRP水平,判定臨床療效.結果 治療1週後,觀察組超聲心動圖檢查等容舒張時間( IVRT )為(83. 5 ± 9. 7)ms,E峰減速時間( DT )為(125. 7 ± 14. 2)ms,顯著低于對照組的(90. 4 ± 10. 2)ms和(154. 6 ± 15. 5)ms (P<0.05),而舒張早期心室充盈血流峰值/舒張晚期血流峰值(E/A)為1.37±0.24,顯著高于對照組的1.10±0.21(P<0.05);觀察組治療後的 BNP為(89. 2 ± 21. 1)pg/mL,CRP為(4. 8 ± 1. 6)mg/L,明顯低于對照組的(107. 2 ± 24. 6)pg/mL和(7. 3 ± 2. 3)mg/L ( P < 0. 05);觀察組治療後的心率(HR)為(74. 8 ± 13. 6)次 /分,收縮壓(SBP)為(109. 5 ± 18. 3)mmHg,明顯低于對照組的( 80. 4 ± 12. 0 )次/分和(113. 3 ± 15. 7)mmHg( P<0. 05);6 min 步行距離為(327. 4 ± 58. 4)m,顯著高于對照組的(295. 3 ± 60. 1)m ( u=3. 730,P<0. 01);兩組患者低血壓、轉氨酶升高等不良反應率比較,差異無統計學意義(χ2 =0. 009,P=0. 923);觀察組治療總有效率為92. 86%,顯著高于對照組的83. 70%(χ2=3. 890,P=0. 049).結論 rhBNP治療DHF能有效降低神經內分泌激素和炎性水平,改善心室舒張功能,提高運動耐量,療效顯著,且安全可靠.
목적 탐토중조인뇌리납태( rhBNP )치료서장성심력쇠갈( DHF )적림상료효급대B형뇌리납태(BNP)、C반응단백( CRP )수평적영향.방법 선취의원수치적DHF환자190례,거취진일기수궤분위관찰조98례화대조조92례,균급여상규항심력쇠갈치료,관찰조환자가용rhBNP,7 d후행초성심동도검사,병채혈검측BNP화CRP수평,판정림상료효.결과 치료1주후,관찰조초성심동도검사등용서장시간( IVRT )위(83. 5 ± 9. 7)ms,E봉감속시간( DT )위(125. 7 ± 14. 2)ms,현저저우대조조적(90. 4 ± 10. 2)ms화(154. 6 ± 15. 5)ms (P<0.05),이서장조기심실충영혈류봉치/서장만기혈류봉치(E/A)위1.37±0.24,현저고우대조조적1.10±0.21(P<0.05);관찰조치료후적 BNP위(89. 2 ± 21. 1)pg/mL,CRP위(4. 8 ± 1. 6)mg/L,명현저우대조조적(107. 2 ± 24. 6)pg/mL화(7. 3 ± 2. 3)mg/L ( P < 0. 05);관찰조치료후적심솔(HR)위(74. 8 ± 13. 6)차 /분,수축압(SBP)위(109. 5 ± 18. 3)mmHg,명현저우대조조적( 80. 4 ± 12. 0 )차/분화(113. 3 ± 15. 7)mmHg( P<0. 05);6 min 보행거리위(327. 4 ± 58. 4)m,현저고우대조조적(295. 3 ± 60. 1)m ( u=3. 730,P<0. 01);량조환자저혈압、전안매승고등불량반응솔비교,차이무통계학의의(χ2 =0. 009,P=0. 923);관찰조치료총유효솔위92. 86%,현저고우대조조적83. 70%(χ2=3. 890,P=0. 049).결론 rhBNP치료DHF능유효강저신경내분비격소화염성수평,개선심실서장공능,제고운동내량,료효현저,차안전가고.
Objective To observe and explore the efficacy of rhBNP in treatment of DHF and its effects on BNP and CRP. Methods 190 admitted DHF patients were selected and randomized into observation group ( 98 cases ) and control group ( 92 cases ) according to clini-cal visit odds number. The control group was given conventional anti heart failure treatment, based on this the observation group was added with rhBNP. 7 d later, patients were reconducted with ultrasonic beckoning graph examination and blood testing, meanwhile clinical efficacy of 2 groups were determined. Results After 1 week's treatment, sovolumic relaxation time ( IVRT ) ( 83. 5 ± 9. 7 ) ms, E peak decel-eration time ( DT ) ( 125. 7 ± 14. 2 ) ms of the observation group were significantly lower than ( 90. 4 ± 10. 2 ) ms, ( 154. 6 ± 15. 5 ) ms of the control group, and early diastolic ventricular filling flow peak to late diastolic peak flow ( E/A ) 1. 37 ± 0. 24 was significantly higher than the control group's 1. 10 ± 0. 21 ( P < 0. 05 ) . The BNP ( 89. 2 ± 21. 1 ) pg/mL, CRP ( 4. 8 ± 1. 6 ) mg/L of the observation group after treat-ment were significantly lower than control group's ( 107. 2 ± 24. 6 ) pg/mL, ( 7. 3 ± 2. 3 ) mg/L ( P < 0. 05 ) . The HR ( 74. 8 ± 13. 6 ) times/min, SBP ( 109. 5 ± 18. 3 ) mmHg of the observation group were significantly lower than control group ' s ( 80. 4 ± 12. 0 ) times /min , (113.3±15.7)mmHg(P < 0.05),6 min walking quantity(327.4±58.4)m was significantly longer than the control group's(295.3±60.1)m ( u=3. 730, P < 0. 001 );the 2 groups' adverse reaction ratio, such aslow blood pressure, serum transaminase rising had no statistical difference (χ2 =0. 009, P=0. 923 ) . The overall efficiency ratio of observation group ( 92. 86% ) was significantly higher than control group's ( 83. 70% ) (χ2=3. 890, P=0. 049 ) . Conclusion rhBNP treatment of DHF can effectively reduce the neuroendocrine hormones and inflammatory level, improve left ventricular diastolic function, improve exercise tolerance, and further improve clinical efficacy, with clinical safety.
